Alto Neuroscience, Inc.(ANRO)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ANRO Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Alto Neuroscience, Inc. (ANRO), a Healthcare sector company. ANRO is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Alto Neuroscience, Inc. reports net income of $-27.6M, free cash flow of $-19.8M. Top institutional holders of ANRO by reported 13-F value include Alpha Wave Global, Commodore Capital, BlackRock, based on the most recent SEC filings. ANRO trades on the NYSE exchange and files with the SEC under CIK 1999480. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANRO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alto Neuroscience, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-27.6M
Free Cash Flow
Q2 2026
$-19.8M
ROIC
Q2 2026
-49.5%
D/E Ratio
Q2 2026
0.07
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProNet Income
-2.9% YoYOperating Income
+3.3% YoYEPS (Diluted)
+12.4% YoYTotal Assets
+4.0% YoYTotal Debt
+63.4% YoYOp. Cash Flow
-9.2% YoYFree Cash Flow
-4.6% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net Income | $-63.2M -2.9% | $-61.4M -69.2% | $-36.3M | — |
| Operating Income | $-66.4M +3.3% | $-68.6M -81.5% | $-37.8M | — |
| EPS (Diluted) | $-2.19 +12.4% | $-2.50 -79.9% | $-1.39 | — |
| Total Assets | $184.7M +4.0% | $177.5M +104.9% | $86.6M | — |
| Total Debt | $16.8M +63.4% | $10.3M +4.0% | $9.9M | — |
| Operating Cash Flow | $-51.8M -9.2% | $-47.4M -41.8% | $-33.4M | — |
| Free Cash Flow | $-51.8M -4.6% | $-49.5M -45.9% | $-33.9M | — |
Get alerted when ANRO's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Alto Neuroscience, Inc. including:
Top Institutional Holders of ANRO
Alpha Wave Global, LP
$97.8M3,707,757 shCommodore Capital LP
$71.9M2,723,196 shBlackRock, Inc.
$56.0M2,121,009 shPERCEPTIVE ADVISORS LLC
$42.5M1,609,893 shADAGE CAPITAL PARTNERS GP, L.L.C.
$42.2M1,600,000 shVANGUARD CAPITAL MANAGEMENT LLC
$36.7M1,389,477 shSpruce Street Capital LP
$35.7M1,353,047 shVivo Capital, LLC
$31.9M1,208,858 shFRANKLIN RESOURCES INC
$26.7M1,013,307 shARMISTICE CAPITAL, LLC
$22.8M864,000 sh
| Fund | Value | Shares |
|---|---|---|
| Alpha Wave Global, LP | $97.8M | 3,707,757 |
| Commodore Capital LP | $71.9M | 2,723,196 |
| BlackRock, Inc. | $56.0M | 2,121,009 |
| PERCEPTIVE ADVISORS LLC | $42.5M | 1,609,893 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $42.2M | 1,600,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | $36.7M | 1,389,477 |
| Spruce Street Capital LP | $35.7M | 1,353,047 |
| Vivo Capital, LLC | $31.9M | 1,208,858 |
| FRANKLIN RESOURCES INC | $26.7M | 1,013,307 |
| ARMISTICE CAPITAL, LLC | $22.8M | 864,000 |
More Healthcare Companies
View all Healthcare →Put ANRO on your watchlist
Track score changes the day Alto Neuroscience, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ANRO a good stock to buy?
13F Pro's AI-powered analysis of Alto Neuroscience, Inc. (ANRO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANRO are available on the ANRO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. ANRO is classified as a small company.
Which hedge funds own ANRO?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANRO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alto Neuroscience, Inc.'s investment landscape.